Success pregnancy rate after use of intralipid in recurrent pregnancy loss
DOI:
https://doi.org/10.65759/q601bv90Keywords:
Recurrent pregnancy loss, Recurrent miscarriage, Intralipid, Lipid emulsion therapy, Live birth rateAbstract
Background: Recurrent pregnancy loss (RPL) is a multifactorial condition, and immunological therapies have been explored in women with recurrent miscarriage or RPL when immune dysregulation is suspected. This review evaluated pregnancy outcomes after intralipid therapy in women with RPL. Methods: A systematic review based on PRISMA principles was conducted using PubMed, Embase, Scopus, and the Cochrane Library. We consider original studies evaluating intralipid or lipid emulsion therapy in women with RPL, recurrent miscarriage, or related reproductive failure populations and reporting pregnancy outcomes. Data on study characteristics, treatment regimens, and outcomes were extracted and analyzed qualitatively. Results: Four studies published between 2015 and 2025 were included, conducted in China, the United States, France, and Japan. Study designs included one prospective randomized trial, one comparative study, and two retrospective cohort studies. One study focused on an unexplained recurrent spontaneous abortion population, while the others included mixed recurrent pregnancy loss miscarriage and recurrent implantation failure populations. Intralipid showed outcomes comparable to intravenous immunoglobulin in two studies, a significantly higher live birth frequency than controls in one recurrent miscarriage subgroup, and no clear improvement versus historical controls in another study. Conclusions: intralipid have benefit in selected women with RPL, and results remain inconsistent and limited by heterogeneous populations and study designs.
References
1. Ford HB, Schust DJ. Recurrent Pregnancy Loss: Etiology, Diagnosis, and Therapy. vol. 2. 2009.
2. El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: Current perspectives. Int J Womens Health 2017;9:331–45. https://doi.org/10.2147/IJWH.S100817.
3. Turesheva A, Aimagambetova G, Ukybassova T, Marat A, Kanabekova P, Kaldygulova L, et al. Recurrent Pregnancy Loss Etiology, Risk Factors, Diagnosis, and Management. Fresh Look into a Full Box. J Clin Med 2023;12. https://doi.org/10.3390/jcm12124074.
4. Evaluation and treatment of recurrent pregnancy loss: A committee opinion. Fertil Steril 2012;98:1103–11. https://doi.org/10.1016/j.fertnstert.2012.06.048.
5. Atik RB, Christiansen OB, Elson J, Kolte AM, Lewis S, Middeldorp S, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open 2023;2023. https://doi.org/10.1093/hropen/hoad002.
6. Shahine L, Lathi R. Recurrent pregnancy loss: Evaluation and treatment. Obstet Gynecol Clin North Am 2015;42:117–34. https://doi.org/10.1016/j.ogc.2014.10.002.
7. Garmendia JV, De Sanctis CV, Hajdúch M, De Sanctis JB. Exploring the Immunological Aspects and Treatments of Recurrent Pregnancy Loss and Recurrent Implantation Failure. Int J Mol Sci 2025;26. https://doi.org/10.3390/ijms26031295.
8. Carp H. Immunotherapy for recurrent pregnancy loss. Best Pract Res Clin Obstet Gynaecol 2019;60:77–86. https://doi.org/10.1016/j.bpobgyn.2019.07.005.
9. Vomstein K, Feil K, Strobel L, Aulitzky A, Hofer-Tollinger S, Kuon RJ, et al. Immunological risk factors in recurrent pregnancy loss: Guidelines versus current state of the art. J Clin Med 2021;10:1–21. https://doi.org/10.3390/jcm10040869.
10. Sfakianoudis K, Rapani A, Grigoriadis S, Pantou A, Maziotis E, Kokkini G, et al. The role of uterine natural killer cells on recurrent miscarriage and recurrent implantation failure: From pathophysiology to treatment. Biomedicines 2021;9. https://doi.org/10.3390/biomedicines9101425.
11. Fukui A, Kamoi M, Funamizu A, Fuchinoue K, Chiba H, Yokota M, et al. NK cell abnormality and its treatment in women with reproductive failures such as recurrent pregnancy loss, implantation failures, preeclampsia, and pelvic endometriosis. Reprod Med Biol 2015;14:151–7. https://doi.org/10.1007/s12522-015-0207-7.
12. Guerrero B, Hassouneh F, Delgado E, Casado JG, Tarazona R. Natural killer cells in recurrent miscarriage: An overview. J Reprod Immunol 2020;142. https://doi.org/10.1016/j.jri.2020.103209.
13. Canella PRBC, Barini R, Carvalho P de O, Razolli DS. Lipid emulsion therapy in women with recurrent pregnancy loss and repeated implantation failure: The role of abnormal natural killer cell activity. J Cell Mol Med 2021;25:2290–6. https://doi.org/10.1111/jcmm.16257.
14. Kumar P, Marron K, Harrity C. Intralipid therapy and adverse reproductive outcome: is there any evidence? Reproduction and Fertility 2021;2:173–86. https://doi.org/10.1530/RAF-20-0052.
15. Meng L, Lin J, Chen L, Wang Z, Liu M, Liu Y, et al. Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion. Arch Gynecol Obstet 2016;294:29–39. https://doi.org/10.1007/s00404-015-3922-8.
16. Plaçais L, Kolanska K, Kraiem Y Ben, Cohen J, Suner L, Bornes M, et al. Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review. European Journal of Obstetrics and Gynecology and Reproductive Biology 2020;252:100–4. https://doi.org/10.1016/j.ejogrb.2020.06.017.
17. Martini AE, Jasulaitis S, Fogg LF, Uhler ML, Hirshfeld Cytron JE. Evaluating the utility of intralipid infusion to improve live birth rates in patients with recurrent pregnancy loss or recurrent implantation failure. J Hum Reprod Sci 2018;11:261–8. https://doi.org/10.4103/jhrs.JHRS_28_18.
18. Yamaya A, Fukui A, Kawai K, Yano M, Honda H, Nakagawa K, et al. A Comparative Study of Intravenous Immunoglobulin and Lipid Emulsion in Patients With Reproductive Failures Associated With NK Cell Abnormalities. Reprod Med Biol 2025;24. https://doi.org/10.1002/rmb2.12662.
